Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)

NCT06806228 is registered in ClinicalTrials.gov with Petrov, Andrey as lead sponsor.

NCT NCT06806228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06806228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
Lead sponsor
Petrov, Andrey
Phase
Phase 1
Overall status
Suspended
Start date
May 20, 2026
Completion date
December 10, 2027
Enrollment
10 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse midline glioma, h3 k27m-mutant, gbm, giant cell glioblastoma, glioblastoma multiforme, gliosarcoma